GlassScriptPhysician profile
Khyati C Patel
NPI 1881822773
$5,688.81
in general payments reported to CMS, 2019-2025
25 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $252 · 2021: $487 · 2022: $795 · 2023: $1,152 · 2024: $1,113 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,053 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.53 |
| Education | $482.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,108.71 | 2019-2025 | |
| Janssen Biotech, INC. | $909.06 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $663.81 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $458.48 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $371.34 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $344.04 | 2019-2025 | Adbry |
| Galderma Laboratories, L.P. | $253.60 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $228.42 | 2022-2024 | Sotyktu |
| Pfizer INC. | $204.41 | 2019-2025 | |
| Amgen INC. | $151.29 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $138.30 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $133.75 | 2022-2025 | |
| Dermavant Sciences, INC. | $100.44 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.15 | 2024-2025 | Spevigo |
| Ani Pharmaceuticals, INC. | $78.07 | 2024-2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.71 | 2019-2024 | Cabtreo |
| Lilly USA, LLC | $63.89 | 2019-2022 | |
| Incyte Corporation | $63.51 | 2022-2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $58.77 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $55.63 | 2019-2023 | |
| Organon LLC | $44.69 | 2025 | Vtama |
| Genentech USA, INC. | $35.93 | 2023-2024 | Erivedge |
| Botanix Sb INC | $26.61 | 2025 | Sofdra |
| Celgene Corporation | $19.27 | 2019 | |
| Almirall LLC | $18.93 | 2025 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khyati Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.